- Circassia Pharmaceuticals said it had launched its lung disease treatment in the US, 'significantly' boosting its portfolio of marketed respiratory products.

The company announced the launch of its lung disease treatment Duaklir - used to treat chronic obstructive pulmonary disease (COPD) -- at the American College of Chest Physicians' CHEST Annual Meeting 2019.

Duaklir had been approved by the United States Food and Drug Administration based on a broad clinical database.

At 9:22am: [LON:CIR] Circassia Pharmaceuticals Plc share price was -0.38p at 16.8p

Story provided by